Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Prostate Cancer
Interventions: Docetaxel, Dexamethasone, Estramustine, Zoladex, Casodex, Radical Prostatectomy; Drug · Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 499
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more

Conditions: Prostate Cancer
Interventions: Genistein Combined Polysaccharide (GCP); Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Male only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University Urological Associates Inc.; Other
Eligibility: 50 Years to 74 Years · Male only
Enrollment: 6,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Prostate Cancer
Interventions: Pembrolizumab, Olaparib, Androgen Deprivation Therapy, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: Zin W Myint; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Lexington, Kentucky • Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Radiation Therapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions: active surveillance, Sunphenon, laboratory biomarker analysis, Questionnaire Administration; Other · Drug
Lead sponsor: Sanjay Gupta PhD; Other
Eligibility: 45 Years to 85 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab; Drug · Biological
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: San Francisco, California • Evergreen Park, Illinois • Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Avelumab; Drug
Lead sponsor: Andrew J. Armstrong, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer Patients Undergoing External Radiation and Seed Implantation
Interventions: Not listed
Lead sponsor: Dattoli Cancer Center and Brachytherapy Research Institute; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 60 participants
Timeline: 2005
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Prostate Cancer
Interventions: Lenalidomide, Docetaxel, Prednisone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: New York, New York

Conditions: Prostate Cancer Patients, Hereditary Cancer, Genetic Testing
Interventions: Print Genetic Education Guide, Digital Guide Genetic Education Guide, Enhanced Usual Care; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New Brunswick, New Jersey

Conditions: Prostate Cancer
Interventions: Enzalutamide, Abiraterone, Placebo for Enzalutamide, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 6
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Virginia Beach, Virginia

Conditions: Prostate Cancer
Interventions: High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer Metastatic
Interventions: ADI-212, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Adicet Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
Interventions: I-131-1095, Enzalutamide; Drug
Lead sponsor: Progenics Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 15 more

Conditions: Elderly, Prostate Cancer
Interventions: LHRH Agonist Therapy Discontinuation; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 70 Years and older · Male only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Prostate Cancer, Castration-resistant, Metastatic
Interventions: testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer Survivor, Prostate Carcinoma
Interventions: Written Information, Prescription, Technology, Coaching; Behavioral
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Portland, Oregon

Conditions: Prostatic Neoplasms
Interventions: Gallium-68 citrate, Positron Emission Tomography (PET); Drug · Procedure
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Prostate Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 70 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Prostate Cancer
Interventions: AZD8359; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Orlando, Florida • East Brunswick, New Jersey • Hackensack, New Jersey + 1 more

Conditions: Healthy
Interventions: Isotopically labeled lycopene, phytoene or phytofluene; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Cancer
Interventions: Estramustine, Taxol; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Effects of GCP on Prostate Cancer.

The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage

Pembro With Radiation With or Without Olaparib

A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

Expanding Genetic Access for Prostate Cancer Survivors

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy

A Phase 1/2 Trial of ADI-212 in mCRPC

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer

Internet-Based Exercise and Diet Support in Prostate Cancer Survivors

Gallium-68 Citrate PET Used in Prostate Cancer

Assessing Depression in a Geriatric Cancer Population

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma